Drugs / XTX202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05052268 | Jan 2022 → Mar 2025 | neoplasm | Xilio Development, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTX202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05052268 ↗ |
| Modality | Protein / enzyme biologic | “an engineered IL-2 prodrug with its activity masked” NCT05052268 ↗ |